Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.
Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page
- Check6 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check13 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference1%
- Check20 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference1%
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.1%
- Check56 days agoChange DetectedA new phase II study has been added to evaluate the effectiveness of pembrolizumab in increasing disease-free survival in patients with recurrent squamous cell carcinoma of the head and neck following salvage surgery, while several previous entries, including those related to Ezra Cohen, have been removed.SummaryDifference12%
- Check63 days agoChange DetectedThe status has changed from 'Active, not recruiting' to 'Unknown status'.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.